


Amendments to the Claims

1. (Original) A compound of the formula:

[Formula 1]




(wherein:

R¹ is optionally substituted aralkyl;
R² and R³ are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for "optionally substituted" is a noncyclic group);
R⁴ is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in "optionally substituted formylamino", "optionally substituted carbamoyl" and "optionally substituted amino" may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl), a pharmaceutically acceptable salt or a solvate thereof (except for Compound (I-A) shown in Table 1 below).

[Table 1]

[Formula I-A]



Compound No.	R ²	R ³	R ⁴
20	H	CH ₂ CH ₂ OMe	H
27	H	Me	NHMs
28	H	CH ₂ CH ₂ OMe	NHMs
29	H	i-Pr	NHMs
85	Me	Me	H
86	H	NHMe	H
87	H	NMe ₂	H
88	H	OMe	H
89	H	H	H
90	H	Me	H
91	H	Et	H
92	H	i-Pr	H
126	H	CH ₂ CH ₂ NMe ₂	H
160	H	CH ₂ CH ₂ OMe	NHCOCH ₂ OMe
161	H	CH ₂ CH ₂ OMe	NHCOCH ₂ CH ₂ CO ₂ Et
162	H	CH ₂ CH ₂ OMe	NHCOCH ₂ CO ₂ Et
163	H	CH ₂ CH ₂ OMe	NHCOOEt
164	H	CH ₂ CH ₂ OMe	NHCOCH ₂ CH ₂ OMe
165	H	CH ₂ CH ₂ OMe	NHCO-thiophene
180	H	CH ₂ CH ₂ OMe	Ph-CH ₂ OH
181	H	NMe ₂	Ph-CH ₂ OH

(Me=methyl; i-Pr=isopropyl; Et=ethyl; Ms=methanesulfonyl; thiophene=thiophene; Ph=phenyl)

2. (Original) The compound according to claim 1, wherein R¹ is p-fluorobenzyl, a pharmaceutically acceptable salt or a solvate thereof.

3. (Original) The compound according to claim 1, wherein R² is hydrogen; R³ is optionally substituted alkyl (substituent: lower alkoxy, amino, cyano, hydroxy, carboxy optionally substituted with lower alkyl, or lower alkoxy carbonyl), or optionally substituted amino (substituent: lower alkyl), a pharmaceutically acceptable salt or a solvate thereof.

4. (Original) The compound according to claim 1, wherein R² is hydrogen; R³ is CH₂CH₂OCH₃, CH₂CH₂OEt, CH₂CH₂COOCH₃, CH₂CH₂CH₂OCH₃, CH₂CH₂CH₂O(i-Pr), N(CH₃)₂, CH₂CH₂CN, CH₂CH₂N(CH₃)₂, CH₂CH₂N(i-Pr)₂, CH₂CH₂CH₂N(CH₃)₂,

$\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Et})_2$, $\text{CH}(\text{CH}_3)\text{CH}_2\text{OH}$, $\text{CH}(\text{CH}_3)\text{COOCH}_3$ or $\text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{CH}_3$, a pharmaceutically acceptable salt or a solvate thereof.

5. (Original) The compound according to claim 1, wherein R^4 is optionally substituted carboxy, optionally substituted carbamoyl (provided that substituent on amino may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted formylamino, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted heteroaryl, a pharmaceutically acceptable salt or a solvate thereof.

6. (Original) The compound according to claim 1, wherein in R^4 , a substituent for “optionally substituted carboxy” is lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, optionally substituted amino lower alkyl, or optionally substituted heterocyclic group;

a substituent for “optionally substituted formylamino” is lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, optionally substituted carbamoyl lower alkyl, optionally substituted lower alkoxy, optionally substituted amino, or optionally substituted carbamoyl;

a substituent for “optionally substituted carbamoyl” is lower alkyl, optionally substituted lower alkyl (substituent: hydroxy, lower alkoxy, halogen, cyano, optionally substituted amino, optionally substituted lower alkoxy, carbamoyl or aryloxy), cycloalkyl, cycloalkyl lower alkyl, optionally substituted heterocyclic group, optionally substituted heterocyclic group lower alkyl, optionally substituted aryl, optionally substituted aryloxy lower alkyl, optionally substituted aralkyl, optionally substituted carbamoyl lower alkyl, optionally substituted lower alkoxy, optionally substituted amino, optionally substituted alkenyl, or optionally substituted alkynyl;

a substituent for “optionally substituted amino” is lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, optionally substituted heterocyclic group, or optionally substituted carbamoyl lower alkyl;


a substituent for “optionally substituted alkyl” or “optionally substituted alkenyl” is hydroxy, halogen, optionally substituted heterocyclic group, optionally substituted

lower alkoxy, optionally substituted amino, optionally substituted carbamoyl, or optionally substituted carboxy;

a substituent for “optionally substituted aryl” or “optionally substituted heteroaryl” is hydroxy, lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, optionally substituted aminoalkyl, optionally substituted carbamoyl lower alkyl, optionally substituted lower alkoxy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted alkenyl, optionally substituted carboxy, optionally substituted carboxyalkyl, optionally substituted sulfamoyl, or optionally substituted sulfamoylalkyl (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted amino” or “optionally substituted carbamoyl” may form an optionally- substituted N-atom containing heterocyclic ring together with an adjacent N atom), a prodrug, a pharmaceutically acceptable salt or a solvate thereof.

7. (Original) The compound according to claim 1, wherein R⁴ is a group shown below, a pharmaceutically acceptable salt or a solvate thereof.

[Formula 2]



(wherein, Me is methyl; Ac is acetyl; Ms is methanesulfonyl)

8. (Currently amended) The compound according to claim-45, wherein R¹ is p-fluorobenzyl and R⁴ is a group recited in claim 5, a pharmaceutically acceptable salt or a solvate thereof.
9. (Currently amended) The compound according to claim-47, wherein R¹ is p-fluorobenzyl and R⁴ is a group described in claim 7, a pharmaceutically acceptable salt or a solvate thereof.
10. (Currently amended) The compound according to claim-47, wherein R¹ is p-fluorobenzyl; R² is hydrogen; R³ is CH₂CH₂OCH₃, N(CH₃)₂, CH₂CH₂CN, CH₂CH₂N(CH₃)₂, CH₂CH₂CH₂N(CH₃)₂, or CH₂CH(OH)CH₂CH₃; R⁴ is a group described in claim 7, a pharmaceutically acceptable salt or a solvate thereof.
11. (Currently amended) A pharmaceutical composition comprising the compound according to any of claims 1 to 10 claim 1, a pharmaceutically acceptable salt or a solvate thereof.
12. (Original) A pharmaceutical composition according to claim 11, wherein it is an HIV integrase inhibitor.
13. (New) A pharmaceutical composition comprising the compound according to claim 2, a pharmaceutically acceptable salt or a solvate thereof.
14. (New) A pharmaceutical composition comprising the compound according to claim 3, a pharmaceutically acceptable salt or a solvate thereof.
15. (New) A pharmaceutical composition comprising the compound according to claim 4, a pharmaceutically acceptable salt or a solvate thereof.

16. (New) A pharmaceutical composition comprising the compound according to claim 5, a pharmaceutically acceptable salt or a solvate thereof.
17. (New) A pharmaceutical composition comprising the compound according to claim 6, a pharmaceutically acceptable salt or a solvate thereof.
18. (New) A pharmaceutical composition comprising the compound according to claim 7, a pharmaceutically acceptable salt or a solvate thereof.
19. (New) A pharmaceutical composition comprising the compound according to claim 8, a pharmaceutically acceptable salt or a solvate thereof.
20. (New) A pharmaceutical composition comprising the compound according to claim 9, a pharmaceutically acceptable salt or a solvate thereof.
21. (New) A pharmaceutical composition comprising the compound according to claim 10, a pharmaceutically acceptable salt or a solvate thereof.